Vemurafenib is a selective BRAF inhibitor that prevents the growth of cancer cells by inhibiting the activity of BRAF mutant proteins, and is approved for the treatment of unresectable or metastatic melanoma bearing the V600E mutation of BRAF [60]. This evidence concerns the gene BRAF and metastatic melanoma.